Compare TWIN & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | RZLT |
|---|---|---|
| Founded | 1918 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.2M | 326.4M |
| IPO Year | N/A | N/A |
| Metric | TWIN | RZLT |
|---|---|---|
| Price | $16.56 | $2.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $12.00 | $9.14 |
| AVG Volume (30 Days) | 38.9K | ★ 4.0M |
| Earning Date | 02-04-2026 | 02-10-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ 128.02 | N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $348,096,000.00 | N/A |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $10.50 | ★ N/A |
| Revenue Growth | ★ 8.31 | N/A |
| 52 Week Low | $6.16 | $1.07 |
| 52 Week High | $19.63 | $11.46 |
| Indicator | TWIN | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 42.82 |
| Support Level | $15.03 | $3.15 |
| Resistance Level | $19.63 | $3.38 |
| Average True Range (ATR) | 1.09 | 0.26 |
| MACD | -0.17 | 0.11 |
| Stochastic Oscillator | 32.83 | 26.56 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.